These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27469139)

  • 1. A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2.
    Szymanska M; Fosdahl AM; Nikolaysen F; Pedersen MW; Grandal MM; Stang E; Bertelsen V
    J Cell Mol Med; 2016 Oct; 20(10):1999-2011. PubMed ID: 27469139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.
    Klapper LN; Vaisman N; Hurwitz E; Pinkas-Kramarski R; Yarden Y; Sela M
    Oncogene; 1997 May; 14(17):2099-109. PubMed ID: 9160890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis.
    Berger C; Madshus IH; Stang E
    Exp Cell Res; 2012 Dec; 318(20):2578-91. PubMed ID: 22975728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
    Ellebaek S; Brix S; Grandal M; Lantto J; Horak ID; Kragh M; Poulsen TT
    Int J Cancer; 2016 Nov; 139(9):2095-105. PubMed ID: 27342948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody.
    Yu X; Wang L; Shen Y; Wang C; Zhang Y; Meng Y; Yang Y; Liang B; Zhou B; Wang H; Wei H; Lei C; Hu S; Li B
    Mol Immunol; 2017 Jul; 87():300-307. PubMed ID: 28531814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.
    Ben-Kasus T; Schechter B; Lavi S; Yarden Y; Sela M
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3294-9. PubMed ID: 19218427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
    Sak MM; Szymanska M; Bertelsen V; Hasmann M; Madshus IH; Stang E
    Carcinogenesis; 2013 Sep; 34(9):2031-8. PubMed ID: 23698633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody.
    Cheng J; Liang M; Carvalho MF; Tigue N; Faggioni R; Roskos LK; Vainshtein I
    Antibodies (Basel); 2020 Sep; 9(3):. PubMed ID: 32961882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.
    Ren XR; Wei J; Lei G; Wang J; Lu J; Xia W; Spector N; Barak LS; Clay TM; Osada T; Hamilton E; Blackwell K; Hobeika AC; Morse MA; Lyerly HK; Chen W
    Breast Cancer Res; 2012 Jun; 14(3):R89. PubMed ID: 22676470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.
    Neve RM; Nielsen UB; Kirpotin DB; Poul MA; Marks JD; Benz CC
    Biochem Biophys Res Commun; 2001 Jan; 280(1):274-9. PubMed ID: 11162510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
    Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology of HER2 and its importance in breast cancer.
    Yarden Y
    Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand.
    Guillemard V; Nedev HN; Berezov A; Murali R; Saragovi HU
    DNA Cell Biol; 2005 Jun; 24(6):350-8. PubMed ID: 15941387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.
    zum Büschenfelde CM; Hermann C; Schmidt B; Peschel C; Bernhard H
    Cancer Res; 2002 Apr; 62(8):2244-7. PubMed ID: 11956077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
    Scaltriti M; Verma C; Guzman M; Jimenez J; Parra JL; Pedersen K; Smith DJ; Landolfi S; Ramon y Cajal S; Arribas J; Baselga J
    Oncogene; 2009 Feb; 28(6):803-14. PubMed ID: 19060928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells.
    Ram S; Kim D; Ober RJ; Ward ES
    MAbs; 2014; 6(5):1211-9. PubMed ID: 25517306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.